ERBB2 and cancer: Several clinical trials are investigating the safety and efficacy of bispecific CAR T-cell therapies for different cancers, including a HER2/PD-L1 dual-targeting CAR T-cells in patients with HER2-positive solid tumors (NCT04684459).